Additional file 1: of Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction

eTable 1. The care facilities of study subjects during the index acute myocardial infarction. eTable 2. Relative risks of various clinical outcomes in patients receiving different antiplatelet therapies using shared frailty model controlling for 174 individual hospitals. eTable 3. Relative risks of various clinical outcomes in patients receiving different antiplatelet therapies using shared frailty model controlling for 11 different levels of hospitals. (DOCX 20 kb

Relative risk of individual clinical end-point in two composite end-points among E-ZES and EES groups.

<p>The SES group was used as the reference. Abbreviations: CABG: coronary artery bypass grafting; CI: confidence interval; EES: everolimus-eluting stent; E-ZES: Endeavor zotarolimus-eluting stent; HR: hazard ratio; PCI: percutaneous coronary intervention; SES: sirolimus-eluting stent.</p

Clinical end-points of patients receiving SES, E-ZES and EES.

<p>Abbreviations: CI: confidence interval; EES: everolimus-eluting stent; E-ZES: Endeavor zotarolimus-eluting stent; HF: heart failure; HR: hazard ratio; PY: person-year; SES: sirolimus-eluting stent.</p><p>Clinical end-points of patients receiving SES, E-ZES and EES.</p

Flow chart of the study.

<p>Abbreviations: CABG: coronary artery bypass grafting; DES: drug-eluting stent; EES: everolimus-eluting stent; EPC: endogenous progenitor cell; E-ZES: Endeavor zotarolimus-eluting stent; NHI: National Health Insurance; PCI: percutaneous coronary intervention; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent; ZES: zotarolimus-eluting stent.</p

Kaplan-Meier cumulative incidences of different clinical end-points in three stent groups.

<p>All-cause mortality (Panel A), acute coronary events (Panel B), heart failure needing hospitalization (Panel C), cerebrovascular disease (Panel D), and repeated coronary revascularization (Panel E). Abbreviations: EES: everolimus-eluting stent; E-ZES: Endeavor zotarolimus-eluting stent; SES: sirolimus-eluting stent.</p

Additional file 1: Figure S1. of Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study

Patient flow diagram for the COPD cohort. Figure S2. Patient flow diagram for the asthma cohort. Figure S3. Patient flow diagram for the ACO cohort and groups with different ACO definitions. Table S1. Characteristics of the ACO cohort and groups with different ACO definitions at index date. Table S2. Respiratory-related medication use in the 12 months post-index date for the ACO cohort and groups with different ACO definitions. Table S3. All-cause medical utilisation in the asthma, COPD and ACO cohorts in the 12 months post-index date. Table S4. Respiratory-related medical utilisation in the 12 months post-index date for the ACO cohort and groups with different ACO definitions. (PDF 2324 kb

Baseline characteristics of patients who received SES, E-ZES and EES.

<p>Abbreviations: ACEi: angotensin-converting-enzyme inhibitor; ACS: acute coronary syndrome, ARB: angiotensin receptor blocker; EES: everolimus-eluting stent; E-ZES: Endeavor zotarolimus-eluting stent; H₂-blocker: histamine-2 receptor blocker; MI: myocardial infarction; PPI: proton pump inhibitor; SES: sirolimus-eluting stent; SD: standard deviation.</p><p>^aIn accordance with privacy regulations in Taiwan, the exact number of patients is not specified if it is less than 2.</p><p>Baseline characteristics of patients who received SES, E-ZES and EES.</p